Borderline ovarian tumours: A comprehensive review of published evidence

IF 5.9 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Best Practice & Research Clinical Obstetrics & Gynaecology Pub Date : 2026-02-01 Epub Date: 2025-11-25 DOI:10.1016/j.bpobgyn.2025.102688

Kyriaki-Barbara Papalois , Michail Sideris , Samuel George Oxley , Arjun Jeyarajah , Alexandra Lawrence , Elly Brockbank , Saurabh Phadnis , James Dilley , Ranjit Manchanda

{"title":"Borderline ovarian tumours: A comprehensive review of published evidence","authors":"Kyriaki-Barbara Papalois , Michail Sideris , Samuel George Oxley , Arjun Jeyarajah , Alexandra Lawrence , Elly Brockbank , Saurabh Phadnis , James Dilley , Ranjit Manchanda","doi":"10.1016/j.bpobgyn.2025.102688","DOIUrl":null,"url":null,"abstract":"<div><div>Borderline Ovarian Tumours (BOTs) comprise 15–20 % of all epithelial ovarian tumours. BOTs are characterised by increased mitotic activity but lack infiltrative destructive growth and stromal invasion. Several dilemmas and controversies have been discussed in the literature regarding BOT management including surgical approach (radical versus fertility-sparing surgery), surgical route (open versus laparoscopic surgery) and impact on disease recurrence, follow-up protocols/modalities (imaging, serum biomarkers), role of completion surgery, lymph node dissection during staging, adjuvant chemotherapy, as well as use of Hormone-Replacement Therapy (HRT) post-surgery. We performed a structured narrative review on Medline and Cochrane Library Databases to identify studies pertaining to the management of BOTs. Identifying areas of agreement and outstanding uncertainty are integral to optimise robust treatment regimens for BOT management and improve the Quality of Life (QoL) and clinical outcomes for patients. We discuss a framework of recommendations to counsel, manage and follow-up women diagnosed with BOT.</div></div>","PeriodicalId":50732,"journal":{"name":"Best Practice & Research Clinical Obstetrics & Gynaecology","volume":"104 ","pages":"Article 102688"},"PeriodicalIF":5.9000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Obstetrics & Gynaecology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521693425001129","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Borderline Ovarian Tumours (BOTs) comprise 15–20 % of all epithelial ovarian tumours. BOTs are characterised by increased mitotic activity but lack infiltrative destructive growth and stromal invasion. Several dilemmas and controversies have been discussed in the literature regarding BOT management including surgical approach (radical versus fertility-sparing surgery), surgical route (open versus laparoscopic surgery) and impact on disease recurrence, follow-up protocols/modalities (imaging, serum biomarkers), role of completion surgery, lymph node dissection during staging, adjuvant chemotherapy, as well as use of Hormone-Replacement Therapy (HRT) post-surgery. We performed a structured narrative review on Medline and Cochrane Library Databases to identify studies pertaining to the management of BOTs. Identifying areas of agreement and outstanding uncertainty are integral to optimise robust treatment regimens for BOT management and improve the Quality of Life (QoL) and clinical outcomes for patients. We discuss a framework of recommendations to counsel, manage and follow-up women diagnosed with BOT.

Abstract Image

查看原文本刊更多论文

边缘性卵巢肿瘤：对已发表证据的全面回顾

交界性卵巢肿瘤（BOTs）占所有卵巢上皮肿瘤的15 - 20%。BOTs的特征是有丝分裂活性增加，但缺乏浸润性破坏性生长和基质侵袭。文献中已经讨论了关于BOT管理的几个困境和争议，包括手术方式（根治性手术还是保留生育能力的手术）、手术路线（开放手术还是腹腔镜手术）和对疾病复发的影响、随访方案/方式（影像学、血清生物标志物）、完成手术的作用、分期期间的淋巴结清扫、辅助化疗以及术后激素替代疗法（HRT）的使用。我们对Medline和Cochrane图书馆数据库进行了结构化的叙述性回顾，以确定与bot管理有关的研究。确定共识领域和突出的不确定性对于优化BOT管理的有力治疗方案和改善患者的生活质量（QoL）和临床结果是不可或缺的。我们讨论了一个建议框架，以咨询、管理和随访被诊断患有BOT的妇女。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research Clinical Obstetrics & Gynaecology 医学-妇产科学

CiteScore

9.40

自引率

1.80%

发文量

113

审稿时长

54 days

期刊介绍： In practical paperback format, each 200 page topic-based issue of Best Practice & Research Clinical Obstetrics & Gynaecology will provide a comprehensive review of current clinical practice and thinking within the specialties of obstetrics and gynaecology. All chapters take the form of practical, evidence-based reviews that seek to address key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. Management will be described in practical terms so that it can be applied to the individual patient.